Skip to content
drillr.ai

TARS

Tarsus Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$56.25-6.02%

Price as of Jul 20, 2026

TARS news

Tarsus Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

    IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Cl

    Globe Newswire ·

  2. Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

    IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today

    Globe Newswire ·

  3. Tarsus to Participate in Upcoming Investor Conferences

    IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: * William Blair 46(th) Annual Growth Stock Conference on Tuesday, June 2(nd), at 8:00 a.m. PT / 11:00 a.m. ET. * 2026 Jefferies Global Healthcare Conference on Wednesday, June 3(rd), at 8:40 a.m. PT / 11:40 a.m. ET. Live webcasts and additional information can be accessed on the events section of the Tar

    Globe Newswire ·

  4. Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

    Generated first quarter XDEMVY(®) net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a

    Globe Newswire ·

  5. Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

    – A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs. Ca

    Globe Newswire ·